|
|

|
Health Information
|
Friday, September 05, 2008
|
|
Find
more information about this topic from either the Web or the world's best
medical journals by using the search boxes at the top of this page.
|
| |
Lupus Medications
|
Patients
and Providers: Working Together
Educating
Patients About Lupus Medications
Nonsteroidal
Anti-Inflammatory Drugs (NSAIDs)
Antimalarials
Corticosteroids
Immunosuppressives
|
|
|
Medications
are an important aspect of the management of many patients
with SLE. An array of drug therapies is now available,
which has increased the potential for effective treatment
and excellent patient outcomes. Once a person has been
diagnosed with lupus, a treatment plan will be developed
by the doctor based on the person’s age, health, symptoms,
and lifestyle. It should be reevaluated regularly and
revised as necessary to ensure it is as effective as possible.
The goals for treating a patient with lupus include
- reducing
tissue inflammation caused by the disease,
- suppressing
immune system abnormalities that are responsible for
tissue inflammation,
- preventing
flares and treating them when they do occur, and
- minimizing
complication
|
|
|
Patients
and Providers: Working Together
Lupus
patients should work with their doctors to develop their
medication treatment plan. Patients should thoroughly
understand the reason for taking a drug, its action, dose,
administration times, and common side effects. Pharmacists
also can be a good resource for patients in helping them
understand their medication treatment plan. If a patient
experiences a problem believed to be related to a medication,
the patient should notify her or his doctor immediately.
It can be dangerous to suddenly stop taking some medications,
and patients should not stop or change treatments without
first talking to their doctor.
The
array of drugs and the complexity of treatment plans can
be overwhelming and confusing. Newly diagnosed patients
and patients whose treatment plans have changed should
be closely followed and have immediate access to a nurse
or doctor if they are having problems with the prescribed
medications. Most SLE patients do well on lupus medications
and experience few side effects. Those who do experience
negative side effects should not become discouraged, because
alternative drugs are often available.
Health
professionals should review drug treament plans with the
lupus patient at each office visit to determine her or
his understanding of and compliance with the plan. Questions
should be encouraged and additional teaching done to reinforce
or provide additional information as needed. It is important
to note that lupus patients often require drugs for the
treatment of conditions commonly seen with the disease.
Examples of these types of medications include diuretics,
antihypertensives, anticonvulsants, and antibiotics.
This
chapter describes some of the main drugs used to treat
SLE. The information presented is intended as a brief
review and reference. Drug references and other medical
and nursing texts provide more complete and detailed information
regarding the use of each drug and associated nursing
care responsibilities.
|
|
| Educating
Patients About Lupus Medications
Chapter
7, Patient Information contains a Patient Information
Sheet on each category of lupus medication covered here.
The sheets can be used to teach lupus patients about the
medications they may need to take. Each sheet contains
general information about the category of drug, specific
instructions on how and when to take the specific medication
prescribed, information about possible side effects, and
precautions.
Brand
names included in this book are provided as examples only;
their inclusion does not mean that these products are
endorsed by NIH or any other Government agency. Also,
if a particular brand name is not mentioned, this does
not mean or imply that the product is unsatisfactory.
|
|
| Nonsteroidal
Anti-Inflammatory Drugs (NSAIDs)
The
NSAIDs comprise a large
and chemically diverse group of drugs that possess analgesic,
anti-inflammatory, and antipyretic properties. Pain and
inflammation are common problems in patients with SLE,
and NSAIDs are usually the drugs of choice for patients
with mild SLE with little or no organ involvement. Patients
with serious organ involvement may require more potent
anti-inflammatory and immunosuppressive drugs.
Types
of NSAIDs
There are as many as 70 NSAIDs on the market,
and new ones are constantly becoming available. Some can
be purchased as over-the-counter preparations, whereas
larger doses of those drugs or other preparations are
available only by prescription. For example, prescriptions
are required for diclofenac sodium (Voltaren), indomethacin
(Indocin), diflunisal (Dolobid), and nabumetone (Relafen).
Mechanism
of Action and Use
The therapeutic effects of NSAIDs stem
from their ability to inhibit the release of prostaglandins
and leukotrienes, which are responsible for producing
inflammation and pain. NSAIDs are very useful in treating
joint pain and swelling and muscle pain. They may also
be used to treat pleuritic chest pain. An NSAID may be
the only drug needed to treat a mild flare; more active
disease may require additional medications.
Although
all NSAIDs appear to work in the same way, not every one
has the same effect on every person. In addition, patients
may do well on one NSAID for a period of time, then, for
some unknown reason, derive no benefit from it. Switching
the patient to a different NSAID should produce the desired
effects. Patients should use only one NSAID at any given
time.
Side/Adverse
Effects
Gastrointestinal:
Dyspepsia, heartburn, epigastric distress,
and nausea; less frequently, vomiting, anorexia, abdominal
pain, GI bleeding, and mucosal lesions. Misoprostol (Cytotec),
a synthetic prostaglandin that inhibits gastric acid secretion,
may be given to prevent GI intolerance. It prevents gastric
ulcers and their associated GI bleeding in patients receiving
NSAIDs.
Genitourinary:
Fluid retention, reduction in creatinine clearance, and
acute tubular necrosis with renal failure.
Hepatic:
Acute reversible hepatotoxicity.
Cardiovascular:
Hypertension and moderate to severe noncardiogenic pulmonary
edema.
Hematologic:
Altered hemostasis through effects on platelet function.
Other:
Skin eruption, sensitivity reactions, tinnitus, and hearing
loss.
Pregnancy
and Lactation
NSAIDs should be avoided during the first
trimester and just before delivery; they may be used cautiously
at other times during pregnancy. NSAIDs appear in breast
milk and should be used cautiously by breastfeeding mothers.
|
|
|
Considerations
for Health Professionals
Assessment:
History:
Allergy to salicylates, other NSAIDs, cardiovascular
dysfunction, hypertension, peptic ulcer, GI bleeding
or other bleeding disorders, impaired hepatic or
renal function, pregnancy, and lactation
Laboratory
data: Hepatic and renal studies, CBC,
clotting times, urinalysis, serum electrolytes,
and stool for guaiac
Physical:
All body systems to determine baseline data and
alterations in function, skin color, lesions, edema,
hearing, orientation, reflexes, temperature, pulse,
respirations, and blood pressure
Evaluation:
Therapeutic response,
including decreased inflammation and adverse effects
Administration:
With food or milk (to decrease
gastric irritation)
Teaching
points:
See Patient Information Sheets (Chapter
7) on NSAIDs.
|
|
|
|
Antimalarials
This
group of drugs was first developed during World War II
because quinine, the standard treatment for malaria, was
in short supply. Investigators discovered antimalarials
could also be used to treat the joint pain that occurs
with rheumatoid arthritis. Subsequent use of antimalarials
showed that they are effective in controlling lupus arthritis,
skin rashes, mouth ulcers, fatigue, and fever. They have
also been shown to be effective in the treatment of DLE.
Antimalarials are not used to manage more serious, systemic
forms of SLE that affect the organs. It may be weeks or
months before the patient notices that these drugs are
controlling disease symptoms.
Types
of Antimalarials
The drugs most often prescribed are hydroxychloroquine
sulfate (Plaquenil) and chloroquine (Aralen).
Mechanism
of Action and Use
The anti-inflammatory action of these drugs is not well
understood. In some patients who take antimalarials, the
total daily dose of corticosteroids can be reduced. Antimalarials
also affect platelets to reduce the risk of blood clots
and lower plasma lipid levels.
Side/Adverse
Effects
Central Nervous System:
Headache, nervousness, irritability, dizziness, and muscle
weakness.
Gastrointestinal:
Nausea, vomiting, diarrhea, abdominal cramps, and loss
of appetite.
Ophthalmologic:
Visual disturbances and retinal changes manifested by
blurring of vision and difficulty in focusing. A very
serious potential side effect of antimalarial drugs is
damage to the retina. Because of the relatively low doses
used to treat SLE, the risk of retinal damage is small.
However, patients should have a thorough eye examination
before starting this treatment and every 6 months thereafter.
Dermatologic:
Dryness, pruritus, alopecia, skin and mucosal pigmentation,
skin eruptions, and exfoliative dermatitis.
Hematologic:
Blood dyscrasia and hemolysis in patients with glucose
6-phosphate dehydrogenase (G6PD) deficiency.
Pregnancy
Antimalarials are considered to have a
small risk of harming a fetus and should be discontinued
in lupus patients who are attempting to become pregnant.
|
|
|
Considerations
for Health Professionals
Assessment:
History:
Known allergies to the prescribed drugs, psoriasis,
retinal disease, hepatic disease, alcoholism, pregnancy,
and lactation.
Laboratory
data: CBC, liver function tests, and
G6PD deficiency.
Physical:
All body systems to determine baseline data and
alterations in function, skin color and lesions,
mucous membranes, hair, reflexes, muscle strength,
auditory and ophthalmological screening, liver palpation,
and abdominal examination.
Evaluation:
Therapeutic response and side effects.
Administration:
Before or after meals at the same time each day
to maintain drug levels.
Teaching
Points:
See Patient Information Sheets (Chapter 7) on Antimalarials.
|
|
|
|
Corticosteroids
Corticosteroids
are hormones secreted by the cortex of the adrenal gland.
SLE patients with symptoms that do not improve or who
are not expected to respond to NSAIDs or antimalarials
may be given a corticosteroid. Although corticosteroids
have potentially serious side effects, they are highly
effective in reducing inflammation, relieving muscle and
joint pain and fatigue, and suppressing the immune system.
They are also useful in controlling major organ involvement
associated with SLE. These drugs are given in much higher
doses than the body produces and act as potent therapeutic
agents. The decision to use corticosteroids is highly
individualized and is dependent upon the patient’s condition.
Once
the symptoms of lupus have responded to treatment, the
dose is usually tapered until the lowest possible dose
that controls disease activity is achieved. Patients must
be monitored carefully during this time for flares or
recurrence of joint and muscle pain, fever, and fatigue
that can result when the dosage is lowered. Some patients
may require corticosteroids only during active stages
of the disease; those with severe disease or more serious
organ involvement may need long-term treatment.
Treatment
with corticosteroids must not be stopped suddenly if they
have been taken for more than 4 weeks. Administration
of corticosteroids causes the body’s own production of
adrenal hormones to slow down or stop, and adrenal insufficiency
will result if the drug is stopped suddenly. Tapering
the dose allows the body’s adrenal glands to recover and
resume production of the natural hormones. The longer
a patient has been on corticosteroids, the more difficult
it is to lower the dose or discontinue use of the drug.
Types
of Corticosteroids
Prednisone (Orason, Meticorten, Deltasone,
Cortan, Sterapred), a synthetic corticosteriod, is most
often used to treat lupus. Others include hydrocortisone
(Cortef, Hydrocortone), methlyprednisolone (Medrol), and
dexamethasone (Decadron). Corticosteroids are available
as a topical cream or ointment for skin rashes, as tablets,
and as an injectable for intramuscular or intravenous
administration.
Mechanism
of Action and Use
The frequently prescribed corticosteroids
are highly effective in reducing inflammation and suppressing
the immune response. These drugs may be used to control
exacerbation of symptoms and are used to control severe
forms of the disease. The drug is usually administered
orally. During periods of serious illness, it may be administered
intravenously; once the patient has been stabilized, oral
administration should be resumed.
Side/Adverse
Effects
Central Nervous
System: Convulsions, headache, vertigo, mood
swings, and psychosis.
Cardiovascular:
Congestive heart failure (CHF) and hypertension.¹
Endocrine:
Cushing’s syndrome, menstrual irregularities, and hyperglycemia.
Gastrointestinal:
GI irritation, peptic ulcer, and weight gain.
Dermatologic:
Thin skin, petechiae, ecchymoses, facial erythema, poor
wound healing, hirsutism,¹ and urticaria.
Musculoskeletal:
Muscle weakness, loss of muscle mass, and osteoporosis.¹
Ophthalmologic:
Increased intraocular pressure, glaucoma, exophthalmos,
and cataracts.¹
Other:
Immunosuppression and increased susceptibility to infection.
¹Long-term
effects.
Pregnancy
and Lactation
Corticosteroids cross the placenta, but
can be used cautiously during pregnancy. They also appear
in breast milk; patients taking large doses should not
breastfeed.
|
|
|
Considerations
for Health Professionals
Assessment:
History:
Hypersensitivity to corticosteroids, tuberculosis,
infection, diabetes, glaucoma, seizure disorders,
peptic ulcer, CHF, hypertension, and liver or kidney
disease
Laboratory
data: Electrolytes, serum glucose, WBC,
cortisol level
Physical:
All body systems to determine baseline data and
alterations in function, weekly weight gain of >5
pounds, GI upset, decreased urinary output, increased
edema, infection, temperature, pulse irregularities,
increased blood pressure, and mental status changes
(e.g., aggression or depression)
Evaluation:
Therapeutic response, including decreased inflammation
and adverse effects
Administration:
With food or milk (to decrease GI symptoms)
Teaching
Points:
See Patient Information Sheets (Chapter 7) on Corticosteroids.
|
|
|
|
Immunosuppressives
Immunosuppressive
agents are generally used to reduce rejection of transplanted
organs. They are also used in serious, systemic cases
of lupus in which major organs such as the kidneys are
affected or in which there is severe muscle inflammation
or intractable arthritis. Because of their steroid-sparing
effect, immunosuppressives may also be used to reduce
or sometimes eliminate the need for corticosteroids, thereby
sparing the patient from undesirable side effects of corticosteroid
therapy.
Immunosuppressives
can have serious side effects. Patients need to understand,
however, that side effects are dose dependent and are
generally reversible by reducing the dose or stopping
the medication.
Types
of Immunosuppressives
A variety of immunosuppressive drugs is available to treat
lupus. Although they have different mechanisms of action,
each type functions to decrease or prevent an immune response.
The immunosuppressives most frequently used with SLE patients
are azathioprine (Imuran), cyclophosphamide (Cytoxan),
methotrexate (Rheumatrex), and cyclosporine (Sundimmune,
Neoral).
Mechanism
of Action and Use
Drugs like azathioprine, methotrexate, and cyclosporine
are referred to as antimetabolite agents. These drugs
block metabolic steps within immune cells and then interfere
with immune function. Cytotoxic drugs like cyclophosphamide
work by targeting and damaging autoantibody-producing
cells, thereby suppressing the hyperactive immune response
and reducing disease activity.
Risks
There are many serious risks associated with the use of
immunosuppressives. They include immunosuppression (resulting
in increased susceptibility to infection), bone marrow
suppression (resulting in decreased numbers of RBCs, WBCs,
and platelets), and development of malignancies.
Side/Adverse
Effects
Dermatologic: Alopecia
(cyclophosphamide only).
Gastrointestinal:
Nausea, vomiting, stomatitis, esophagitis, and hepatotoxicity.
Genitourinary:
Hemorrhagic cystitis, hematuria, amenorrhea,¹ impotence,¹
and gonadal suppression (cyclophosphamide only).²
¹
Temporary or reversible once drug therapy
is discontinued.
² Recovery of function after drug
is discontinued is unpredictable.
Hematologic:
Thrombocytopenia, leukopenia, pancytopenia, anemia, and
myelo-suppression.
Respiratory:
Pulmonary fibrosis.¹
Other:
Increased risk of serious infections or malignancies.
Pregnancy
and Lactation
Use of immunosuppressives presents definite risks to the
fetus. Female patients should use contraceptive measures
during treatment and for 12 weeks after ending azathioprine
therapy. Azathioprine may pass into breast milk, and women
using this drug should consult with their doctors before
breastfeeding.
¹
With high doses.
|
|
|
Considerations
for Health Professionals
Assessment:
History:
Allergy to immunosuppressive drugs, infections,
impaired hepatic or renal function, pregnancy, lactation,
corticosteroid therapy, immunosuppression, and bone
marrow suppression
Laboratory
data: CBC, differential, platelet count,
renal function studies, liver function tests, pulmonary
function tests, chest X ray, and electrocardiogram
(ECG)
Physical:
All body systems to determine baseline data and
alterations in function, temperature, pulse, respirations,
weight, skin color, lesions, hair, and mucous membranes
Evaluation:
Therapeutic response and adverse effects
Administration:
Orally or intravenously. Precaution: Drug
administration protocols can vary. The nurse must
work closely with the prescribing physician to safely
administer the drug and to monitor the patient to
minimize adverse effects and achieve expected outcomes
Teaching
Points:
See Patient Information Sheets (Chapter 7) on Azathioprine
and Cyclophosphamide.
|
|
|
| |
1. Erythematosus 2. Advances 3. Tests 4. Care 5. Medications
6. Psychosocial Aspects 7. Patient Info. 8. Resources
|
|
January 26, 1999
|
|
|
|